Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hansson

Showing results (151-160 of 202) with videos related to

Pageof 21
Sort By:
Journal of the National Cancer Institute|May 21, 1997
Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanomaA Platz, J Hansson, E Månsson-Brahme, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patientsB T Hill, K J Scanlon, J Hansson, et al.
Cellular Immunology|October 1, 1991
Induction of interleukin-1 in human monocytes by the superantigen staphylococcal enterotoxin A requires the participation of T cellsA Gjörloff, H Fischer, G Hedlund, et al.
Journal of Neurochemistry|September 8, 2005
The temperature dependence and involvement of mitochondria permeability transition and caspase activation in damage to organotypic hippocampal slices following in vitro ischemiaAnna Rytter, Carla M P Cardoso, Petra Johansson, et al.
Anticancer Research|July 1, 1997
The Ras farnesylation inhibitor BZA-5B increases the resistance to cisplatin in a human melanoma cell lineT Fokstuen, Y B Rabo, J N Zhou, et al.
The Journal of Experimental Medicine|December 1, 1994
Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expressionM Matsuda, F Salazar, M Petersson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2000
Bladder cancer: allelic deletions at and around the retinoblastoma tumor suppressor gene in relation to stage and gradeT Wada, J Louhelainen, K Hemminki, et al.
Immunotechnology : an International Journal of Immunological Engineering|September 1, 1996
Antibody-targeted superantigens in cancer immunotherapyM Søgaard, J Hansson, M J Litton, et al.
Experimental Neurology|April 8, 2009
Evaluation of putative inhibitors of mitochondrial permeability transition for brain disorders--specificity vs. toxicitySaori Morota, Roland Månsson, Magnus J Hansson, et al.
Acta Neurochirurgica. Supplement|April 9, 2013
Cyclophilin-D inhibition in neuroprotection: dawn of a new era of mitochondrial medicineHiroyuki Uchino, Kiyoshi Hatakeyama, Saori Morota, et al.
Pageof 21

Showing results (151-160 of 202) with videos related to

Sort By:
Pageof 21
Journal of the National Cancer Institute|May 21, 1997
Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanomaA Platz, J Hansson, E Månsson-Brahme, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patientsB T Hill, K J Scanlon, J Hansson, et al.
Cellular Immunology|October 1, 1991
Induction of interleukin-1 in human monocytes by the superantigen staphylococcal enterotoxin A requires the participation of T cellsA Gjörloff, H Fischer, G Hedlund, et al.
Journal of Neurochemistry|September 8, 2005
The temperature dependence and involvement of mitochondria permeability transition and caspase activation in damage to organotypic hippocampal slices following in vitro ischemiaAnna Rytter, Carla M P Cardoso, Petra Johansson, et al.
Anticancer Research|July 1, 1997
The Ras farnesylation inhibitor BZA-5B increases the resistance to cisplatin in a human melanoma cell lineT Fokstuen, Y B Rabo, J N Zhou, et al.
The Journal of Experimental Medicine|December 1, 1994
Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expressionM Matsuda, F Salazar, M Petersson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2000
Bladder cancer: allelic deletions at and around the retinoblastoma tumor suppressor gene in relation to stage and gradeT Wada, J Louhelainen, K Hemminki, et al.
Immunotechnology : an International Journal of Immunological Engineering|September 1, 1996
Antibody-targeted superantigens in cancer immunotherapyM Søgaard, J Hansson, M J Litton, et al.
Experimental Neurology|April 8, 2009
Evaluation of putative inhibitors of mitochondrial permeability transition for brain disorders--specificity vs. toxicitySaori Morota, Roland Månsson, Magnus J Hansson, et al.
Acta Neurochirurgica. Supplement|April 9, 2013
Cyclophilin-D inhibition in neuroprotection: dawn of a new era of mitochondrial medicineHiroyuki Uchino, Kiyoshi Hatakeyama, Saori Morota, et al.
Pageof 21